Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
42 Results for "
P14
" in MedChemExpress (MCE) Product Catalog:
Products (42)
42 Results for "P14" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-P80615
Synonyms: CDK4 inhibitor p16 INK4 antibody;
CDK4I antibody;
CDKN2 antibody;
CDKN2A antibody;
Cell cycle negative regulator beta antibody;
CMM2 antibody;
Cyclin dependent kinase 4 inhibitor A antibody;
Cyclin dependent kinase inhibitor 2A (melanoma p16 inhibits CDK4) antibody;
Cyclin Dependent Kinase Inhibitor 2A antibody;
Cyclin dependent kinase inhibitor 2A isoform 4 antibody;
Cyclin dependent kinase inhibitor 2A isoforms 1/2/3 antibody;
Cyclin dependent kinase inhibitor p16 antibody;
INK4 antibody;
INK4A antibody;
MLM antibody;
MTS1 antibody;
Multiple tumor suppressor 1 antibody;
P14 antibody;
p16 antibody;
P16INK4 antibody;
p16INK4a antibody;
p19 antibody;
p19Arf antibody;
TP16 antibody;
1
Cat. No.: HY-P3598
CAS No.: 57468-16-3
Target:
Research Areas:
Cat. No.: HY-RS12386
Target:
Research Areas:
S100A9 Human Pre-designed siRNA Set A contains three designed siRNAs for S100A9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P10553
CAS No.: 935732-44-8
Cat. No.: HY-N0992
CAS No.: 25577-04-2
Cat. No.: HY-164536
CAS No.: 1848971-16-3
SLCB050 is a compound that blocks the interaction between DX2 and p14/ARF and has anticancer activity. SLCB050 reduces the viability of human lung cancer cells, especially small cell lung cancer cells, in a p14/ARF-dependent manner and induces apoptosis and senescence .
Cat. No.: HY-145338
CAS No.: 2215098-77-2
PI3Kβ-IN-1 (compound (P)-14) is a selective and orally active PI3Kβ inhibitor, with an IC50 of 2 nM .
Cat. No.: HY-P10553A
Cat. No.: HY-181131
CAS No.: 1310059-06-3
Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma .
Cat. No.: HY-P77829
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: S100-A9; Calgranulin-B; Calprotectin L1H subunit; MRP-14; P14; CAGB; MRP14
Species:
Source:
Cat. No.: HY-RS12212
Target:
Research Areas:
RPP14 Human Pre-designed siRNA Set A contains three designed siRNAs for RPP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS02379
Target:
Research Areas:
CDK2AP2 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK2AP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS13999
Target:
Research Areas:
SUB1 Human Pre-designed siRNA Set A contains three designed siRNAs for SUB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS10164
Target:
Research Areas:
Pcolce Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pcolce gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23706
Target:
Research Areas:
Fabp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fabp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
